Exciting Developments from Serina Therapeutics
Serina Therapeutics, Inc. (NYSE American: SER), a leader in clinical-stage biotechnology, is making waves in the medical community. At an upcoming conference, the company will share vital new research findings on its innovative POZ Platform drug delivery technology. The presentation will be conducted by Dr. Randall Moreadith, who serves as the Chief Development Officer at Serina.
A Pioneering Approach to Gene Delivery
At the ACS Spring Meeting and Expo, set to take place in the vibrant city of San Diego, Dr. Moreadith will unveil his presentation titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles." This work is pivotal as it demonstrates the immunogenic profile of Serina’s proprietary POZ-lipid technology.
Through his findings, Dr. Moreadith plans to highlight significant data showing that Serina’s POZ-lipid does not activate an IgM or IgG antibody response upon repetitive dosing in rat models. This is a stark contrast to standard polyethylene glycol (PEG)-lipids typically utilized in existing lipid nanoparticle (LNP) formulations, which have been known to induce a notable antibody response.
Addressing Immunogenic Concerns
Understanding the immunogenic reactions associated with conventional LNPs is crucial for patient safety. Anti-PEG antibodies have been linked with severe adverse reactions during treatments, primarily evidenced in patients receiving PEGylated mRNA vaccines developed by leading pharmaceutical companies. With the absence of such an immune response to the innovative POZ-lipid, Serina Therapeutics may be paving the way for the creation of safer and more efficacious LNP formulations.
About Serina Therapeutics
Serina Therapeutics is focused on developing a robust pipeline of drug candidates aimed at addressing neurological disorders and other health conditions. Their cutting-edge POZ Platform is designed to enhance the effectiveness and safety of various therapeutic modalities, including small molecules, RNA therapies, and antibody-drug conjugates (ADCs). This innovative approach places Serina at the forefront of biotechnology.
Location and Collaboration
Headquartered at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama, Serina is involved in a collaborative ecosystem of research and technology that fosters innovation. This environment not only supports their ongoing research initiatives but also reinforces their commitment to advancing therapeutic solutions.
Connecting with Serina Therapeutics
For those seeking more detailed information about the advancements and initiatives undertaken by Serina Therapeutics, visiting their official website is a great starting point.
Inquiry and Contact Information
For any inquiries, individuals are encouraged to reach out to Stefan Riley at the provided contact details. With a dedicated team ready to assist, Serina is open to engaging with the scientific community and stakeholders interested in their pioneering technologies.
Frequently Asked Questions
What is the POZ Platform developed by Serina Therapeutics?
The POZ Platform is a novel drug delivery technology designed to enhance the safety and efficacy of various therapeutic modalities.
What significant data will Dr. Moreadith present at the ACS meeting?
Dr. Moreadith will present findings that demonstrate the immunogenicity of Serina’s POZ-lipid compared to traditional PEG-lipids.
Why is the absence of an immune response important?
The lack of immune response to the POZ-lipid may lead to safer gene therapy options, reducing the risk of adverse reactions associated with PEG-lipids.
Where is Serina Therapeutics headquartered?
Serina Therapeutics is located at the HudsonAlpha Institute of Biotechnology in Huntsville, Alabama.
How can I reach Serina Therapeutics for more information?
Interested individuals can contact Stefan Riley via email or phone for inquiries related to Serina Therapeutics' technologies and initiatives.
